Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML Treatment According to GIMEMA AML8 and AML10 Protocols
NCT00449319Phase 2Unknown
- Sponsor
- GIMEMA
- Start
- Nov 1998
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of daunorubicin in acute myeloid leukemia (AML), sponsored by GIMEMA. Status: unknown.
02
Drugs
daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00449319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00449319.